-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In a previous phase 1 trial, the oral BCL-2 inhibitor Venetog for the treatment of refractory/relapsed non-Hodgkin’s lymphoma (NHL) achieved an overall response rate (ORR) of 44%
.
The late response rate (CR) in mantle cell lymphoma (MCL) and follicular lymphoma (FL) reached 21% (6/28) and 17% (5/29), respectively; in addition, in the Fahrenheit giant ball Partial remission was also observed in proteinemia (WM) and marginal zone lymphoma (MZL)
Lymphoma
This article reports the long-term prognosis of four cohorts of patients in this phase 1 trial
.
All remissions (n=106) received Venetog monotherapy (200-1200 mg/day) until the disease progressed or intolerable toxicity appeared
.
The ORR, progression-free survival (PFS), duration of remission (DoR) and adverse reactions (AE) were assessed
Remission status and duration of remission in each cohort
Remission status and duration of remission in each cohortAfter a median follow-up of 38.
5 months, the overall median PFS of 106 patients was 5.
4 months (FL, MCL, MZL, and WM PFS were 10.
8, 11.
3, 21.
2, and 30.
4 months, respectively)
.
The overall median DoR was 14.
After a median follow-up of 38.
PFS in MCL and FL patients
PFS in MCL and FL patientsHematological adverse events of all grades are uncommon: neutropenia (19%), anemia (19%) and blood deficiency and love are not reduced (17%), and there is no new thrombocytopenia after 2 years of treatment
.
Non-hematological adverse events included nausea (49%), diarrhea (46%), and fatigue (44%).
Hematological adverse events of all grades are uncommon: neutropenia (19%), anemia (19%) and blood deficiency and love are not reduced (17%), and there is no new thrombocytopenia after 2 years of treatment
In summary, Venetog monotherapy has controllable safety and achieves durable remission in a subgroup of FL, MCL, WM and MZL patients , especially in patients who have obtained CR
Venetoque monotherapy has controllable safety, and achieves long-lasting relief in a subgroup of patients with FL, MCL, WM and MZL.
Original source:
Matthew S.
Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study in this message
